Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

1 ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, ENHERTU is the lead ADC in ...

This study provides compelling evidence that SLC7A11 may serve as a potential therapeutic target for trastuzumab-resistant HER2-positive breast cancer. While the findings are well-supported by robust ...

Some establishment Democrats called for Lt. Gov. Antonio Delgado to resign Tuesday – one day after he announced he’d run in a party primary against Gov. Kathy Hochul. “He shouldn’t be on ...

Progression-free survival longer with vepdegestrant than fulvestrant in subgroup with ESR1 mutations, but not in the overall population ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

After 15 years of trastuzumab in first-line treatment for HER2-positive gastro-oesophageal adenocarcinoma, the bispecific zanidatamab represents a possible replacement for trastuzumab, depending on ...

SECOND-LINE treatment with trastuzumab deruxtecan has been shown to extend overall survival by more than 3 months in patients with advanced HER2-positive gastric or gastroesophageal junction ...

“This analysis showed that ribociclib in combination with letrozole or anastrozole lowered the chance of the cancer returned was safe to use in a broad population of patients with HR-positive, ...